Lung Cancer News and Research

Latest Lung Cancer News and Research

SUVmax predicts outcome in advanced NSCLC

Parameters measured by positron emission tomography with integrated computed tomography at diagnosis can be used to predict outcome following concurrent chemoradiotherapy for stage III non-small-cell lung cancer, research shows.

19 May 2014

HRQoL changes predict survival in NSCLC

Changes in health-related quality of life during treatment may help predict survival in patients with advanced non-small-cell lung cancer, suggest findings from the EORTC 08975 study.

19 May 2014

Researchers identify drugs to slow progression of idiopathic pulmonary fibrosis

Researchers in separate clinical trials found two drugs slow the progression of idiopathic pulmonary fibrosis, a fatal lung disease with no effective treatment or cure, and for which there is currently no therapy approved by the Food and Drug Administration.

19 May 2014

DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

RNA interference (RNAi) is a naturally occurring process, which cells can use to silence, or ‘turn off’ unwanted genes.

From Quest Diagnostics 19 May 2014

Prevalence of heart failure is higher in patients with COPD, finds study

As if increased risks of high blood pressure, respiratory infections, lung cancer and even depression weren't enough, researchers say patients with chronic obstructive pulmonary disease (COPD) have another complication to worry about: heart failure.

19 May 2014

TOLMAR Pharmaceuticals holds exclusive distribution rights to ELIGARD in the U.S. and Puerto Rico

TOLMAR Pharmaceuticals, Inc., focused on specialty pharmaceutical products, today announced that, effective May 8, 2014, the company holds exclusive distribution rights to ELIGARD® (leuprolide acetate for injectable suspension) in the U.S. and Puerto Rico.

16 May 2014

Lung cancer screening guidelines could cost Medicare billions

A study of Medicare beneficiaries with a history of heavy smoking found that new lung cancer screening guidelines would likely double the proportion of lung cancers found at an early stage, but at a steep cost of more than $9 billion over five years.

16 May 2014

Olympus receives Edison Awards for three healthcare products

Olympus, a precision technology leader in designing and delivering innovative solutions in Medical and Surgical Products, among other core businesses, announced today that the company has received Edison Awards for three of its "world's only" products: ENDOEYE FLEX 3D, THUNDERBEAT and the BF-190 Bronchoscope.

From Evident Corporation - Life Sciences 15 May 2014

VisionGate develops LuCED test for early detection of lung cancer

VisionGate Inc., an in vitro diagnostics company that is developing a revolutionary, non-invasive test for the early detection of lung cancer and other applications, announced that positive results from a clinical study of its LuCED lung test will be highlighted in a poster presentation (Abstract #7547) during the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting at McCormick Place in Chicago on Saturday, May 31, 1:15 to 5 p.m. in S Hall A2, poster board 155.

15 May 2014

First Edition: May 15, 2014

Today's headlines include highlights from Wednesday's Senate confirmation hearing -- the second one -- for Sylvia Mathews Burwell, the White House pick to become the next Health and Human Services Secretary.

15 May 2014

Phase I study reveals abemaciclib drug shows evidence of single-agent activity in NSCLC patients

Abemaciclib, an oral drug administered twice daily, currently in development by Eli Lilly and Company (NYSE: LLY), has shown evidence of single-agent activity in patients with advanced non-small cell lung cancer in a Phase I study released ahead of the American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago, Ill.

15 May 2014

CNS stimulant no more effective than placebo for alleviating lung cancer fatigue

Patients with advanced non-small-cell lung cancer who received the central nervous system stimulant modafinil reported no greater reduction in fatigue than patients given placebo, show study results.

13 May 2014

Amrubicin promise for etoposide-naïve SCLC patients

Patients with chemotherapy-refractory small-cell lung cancer may benefit from treatment with the topoisomerase II inhibitor amrubicin, research from Japan suggests.

12 May 2014

Verastem announces expansion of ongoing COMMAND study in Japan

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the expansion of its ongoing COMMAND study to include clinical trial sites in Japan.

12 May 2014

Wake Forest Baptist Medical Center finds novel treatment to keep lung cancer at bay

An old idea of retreating lung tumors with radiation is new again, especially with the technological advances seen in radiation oncology over the last decade.

9 May 2014

ACR now accepts applications for new Lung Cancer Screening Center program

The American College of Radiology (ACR) is now accepting applications for its new ACR Lung Cancer Screening Center program, which recognizes facilities committed to providing quality screening care to patients at the highest risk for lung cancer.

9 May 2014

Clovis Oncology reports net loss of $30.7 million for first quarter 2014

Clovis Oncology, Inc. reported financial results for its first quarter ended March 31, 2014, and provided an update on the Company's clinical development programs for the rest of 2014.

9 May 2014

BTMed, SCCA expand early lung cancer detection program for high risk construction workers

Today, the Building Trades National Medical Screening Program (BTMed) and Seattle Cancer Care Alliance (SCCA) expanded their early lung cancer detection program (ELCD) for high risk construction workers in Western Washington.

9 May 2014

ARIAD provides update on corporate developments, reports Q1 2014 financial results

ARIAD Pharmaceuticals, Inc. today reported financial results for the first quarter of 2014, including revenue from sales of Iclusig® (ponatinib) and licensing agreements. The Company also provided an update on corporate developments.

7 May 2014

Protein molecule seems to slow progression of deadly lung disease

Researchers at the University of Illinois at Chicago College of Medicine have discovered a protein molecule that seems to slow the progression of pulmonary fibrosis, a progressive lung disease that is often fatal three to five years after diagnosis.

7 May 2014